期刊文献+

卵巢癌组织中胃泌素释放肽及其受体的表达 被引量:3

Expression of gastrin-releasing peptide and its receptor in ovarian cancer tissue
下载PDF
导出
摘要 目的:探讨卵巢癌组织中胃泌素释放肽(GRP)和其受体(GRPR)的表达及意义。方法:应用免疫组化技术检测58例卵巢癌、49例良性卵巢上皮性肿瘤和37例因子宫脱垂行子宫切除术要求切除一侧或双侧正常卵巢的卵巢组织中GRP和GRPR蛋白的表达,分析GRP和GRPR蛋白表达与卵巢癌患者临床病理特征的关系以及二者在卵巢癌中表达的关联性。结果:良性卵巢上皮性肿瘤组织和正常卵巢组织中GRP和GRPR的阳性表达率分别为10.2%、6.1%和8.1%、5.4%,卵巢癌组织中分别为44.8%和87.9%,3组相比差异有统计学意义(χ2=24.289和98.289,P均<0.001)。卵巢癌组织分化越差,GRP蛋白表达越高(χ2=7.608,P=0.006);GRPR蛋白表达与卵巢癌的分化程度、临床分期、有无腹水形成有关(χ2=6.849,4.700和8.026,P均<0.05)。卵巢癌组织中GRP和GRPR的表达无关联性(rp=0.194,P=0.131)。结论:GRP和GRPR可能参与了卵巢癌的癌变和进展,GRPR还可能与肿瘤的侵袭转移有关。 Aim:To investigate the expression of gastrin-releasing peptide(GRP)and its receptor(GRPR)in tissue of ovarian cancer(OC).Methods:A total of pathology specimens of 58 patients with OC,49 patients with benign ovarian tumor and 37 patients without tumor were recuited.Immunohistochemistry was used to evaluate the expression level of GRP and GRPR in ovarian tissues.Clinical parameter of age,familial history,grade,stage,type,ascite and lymphatic metastasis were integrated.Results:GRP and GRPR were all overexpression in OC(44.8% and 87.9%)than benign tumor(10.2% and 6.1%)and normal group(8.1% and 5.4%)(χ2=24.289 and 98.289,P0.001).The expression of GRP and GRPR seemed related to poor differentiation(χ2=7.608 and 9.249,P=0.006 and 0.002).GRPR seemed related to stage,differentiation and ascite(χ2=4.700,6.849,and 8.026,P0.05).The expression of GRP and GRPR did not show a correlation(rp=0.194,P=0.131)in OC tissue.Conclusion:GRP and GRPR might participate in the cancergenesis and development of OC,and GRPR seems a possible index of grade malignancy and metastasis.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2011年第4期550-553,共4页 Journal of Zhengzhou University(Medical Sciences)
基金 郑州大学优秀博士基金资助项目200803
关键词 胃泌素释放肽 胃泌素释放肽受体 卵巢癌 gastrin-releasing peptide receptor of gastrin-releasing peptide ovarian cancer
  • 相关文献

参考文献11

  • 1王翠翠,张晓霞,王丽娜,许淑芬,欧健,田海涵.卵巢癌患者血清人激肽释放酶10的检测及其临床意义[J].吉林大学学报(医学版),2010,36(3):540-542. 被引量:8
  • 2王英芳.上皮性卵巢癌组织中P53和Survivin蛋白的表达[J].郑州大学学报(医学版),2007,42(5):935-937. 被引量:6
  • 3Permuth-Wey J,Sellers TA. Epidemiology of ovarian cancer[J]. Methods Mol Biol, 2009, 472:413.
  • 4Fang J, Lu Y, Ouyang K, et al. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo [ J ]. Clin Vaccine Immunol, 2009,16 (7) : 1033.
  • 5Ischia J, Patel O, Shulkes A, et al. Gastrin-releasing peptide : different forms, different functions [ J ]. Biofactors, 2009,35( 1 ) :69.
  • 6Qiao J, Kang J, Ishola TA, et al. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma [ J ]. Proc Natl Acad Sci USA ,2008,105 ( 35 ) : 12891.
  • 7Fleischmann A, Waser B, Reubi JC. Overexpression of gastrin-rele'asing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms[ J]. Cell Oncol, 2007, 29(5): 421.
  • 8Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer[ J]. Biochim Biophys Acta,2006,1766( 1 ) :23.
  • 9Barrette BA,Srivatsa PJ, Cliby WA, et al. Overexpression of P34cdc2 protein kinase in epithelial ovarian carcinoma [ J]. Mayo Clin Proc, 1997,72(10) :925.
  • 10Flores DG, Meurer L, Uberti AF, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain [J]. Brain Res Bu11,2010,82(1/2) :95.

二级参考文献24

共引文献12

同被引文献47

引证文献3

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部